Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Proteomic Profiles in Advanced Age-Related Macular Degeneration Using an Aptamer-Based Proteomic Technology.

Lynch AM, Wagner BD, Weiss SJ, Wall KM, Palestine AG, Mathias MT, Siringo FS, Cathcart JN, Patnaik JL, Drolet DW, Janjic N, Mandava N.

Transl Vis Sci Technol. 2019 Jan 25;8(1):14. doi: 10.1167/tvst.8.1.14. eCollection 2019 Jan.

2.

Pharmacokinetic Properties of DNA Aptamers with Base Modifications.

Gupta S, Drolet DW, Wolk SK, Waugh SM, Rohloff JC, Carter JD, Mayfield WS, Otis MR, Fowler CR, Suzuki T, Hirota M, Ishikawa Y, Schneider DJ, Janjic N.

Nucleic Acid Ther. 2017 Dec;27(6):345-353. doi: 10.1089/nat.2017.0683. Epub 2017 Sep 29.

3.

Fit for the Eye: Aptamers in Ocular Disorders.

Drolet DW, Green LS, Gold L, Janjic N.

Nucleic Acid Ther. 2016 Jun;26(3):127-46. doi: 10.1089/nat.2015.0573. Epub 2016 Jan 12. Review.

4.

Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.

Hirota M, Murakami I, Ishikawa Y, Suzuki T, Sumida S, Ibaragi S, Kasai H, Horai N, Drolet DW, Gupta S, Janjic N, Schneider DJ.

Nucleic Acid Ther. 2016 Feb;26(1):10-9. doi: 10.1089/nat.2015.0567. Epub 2015 Nov 18.

5.

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.

Hamilton M, Wolf JL, Drolet DW, Fettner SH, Rakhit AK, Witt K, Lum BL.

Cancer Chemother Pharmacol. 2014 Mar;73(3):613-21. doi: 10.1007/s00280-014-2390-3. Epub 2014 Jan 29.

PMID:
24474302
6.

A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma.

Colagiovanni DB, Drolet DW, Langlois-Forget E, Piché MP, Looker D, Rosenthal GJ.

Regul Toxicol Pharmacol. 2012 Feb;62(1):115-24. doi: 10.1016/j.yrtph.2011.12.012. Epub 2011 Dec 24.

PMID:
22210450
7.

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.

Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML.

Clin Cancer Res. 2008 Dec 1;14(23):7947-55. doi: 10.1158/1078-0432.CCR-08-0864.

8.

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J.

Br J Cancer. 2006 Aug 21;95(4):450-6. Epub 2006 Aug 1.

9.

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

Lee CP, de Jonge MJ, O'Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J.

Clin Cancer Res. 2006 May 1;12(9):2841-8.

10.
11.

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. Epub 2006 Mar 10.

PMID:
16528532
12.
13.

Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys.

Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA.

Pharm Res. 2000 Dec;17(12):1503-10.

PMID:
11303960
14.

A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX).

Drolet DW, Jenison RD, Smith DE, Pratt D, Hicke BJ.

Comb Chem High Throughput Screen. 1999 Oct;2(5):271-8.

PMID:
10539988
15.

Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys.

Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW.

J Chromatogr B Biomed Sci Appl. 1999 Sep 10;732(1):203-12.

PMID:
10517237
16.

Aptamer affinity chromatography: combinatorial chemistry applied to protein purification.

Romig TS, Bell C, Drolet DW.

J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):275-84.

PMID:
10510781
17.

Purification of a highly modified RNA-aptamer. Effect of complete denaturation during chromatography on product recovery and specific activity.

Bridonneau P, Bunch S, Tengler R, Hill K, Carter J, Pieken W, Tinnermeier D, Lehrman R, Drolet DW.

J Chromatogr B Biomed Sci Appl. 1999 Apr 16;726(1-2):237-47.

PMID:
10348191
18.

Expression patterns of the hepatic leukemia factor gene in the nervous system of developing and adult mice.

Hitzler JK, Soares HD, Drolet DW, Inaba T, O'Connel S, MG Rosenfeld, Morgan JI, Look AT.

Brain Res. 1999 Feb 27;820(1-2):1-11.

PMID:
10023025
19.

Reduced fertility in mice deficient for the POU protein sperm-1.

Pearse RV 2nd, Drolet DW, Kalla KA, Hooshmand F, Bermingham JR Jr, Rosenfeld MG.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7555-60.

20.

An enzyme-linked oligonucleotide assay.

Drolet DW, Moon-McDermott L, Romig TS.

Nat Biotechnol. 1996 Aug;14(8):1021-5.

PMID:
9631044
21.
22.

POU-domain proteins: structure and function of developmental regulators.

Wegner M, Drolet DW, Rosenfeld MG.

Curr Opin Cell Biol. 1993 Jun;5(3):488-98. Review.

PMID:
8352967
23.
24.
25.

TEF, a transcription factor expressed specifically in the anterior pituitary during embryogenesis, defines a new class of leucine zipper proteins.

Drolet DW, Scully KM, Simmons DM, Wegner M, Chu KT, Swanson LW, Rosenfeld MG.

Genes Dev. 1991 Oct;5(10):1739-53.

26.

Increase in cyclic AMP levels by relaxin in newborn rhesus monkey uterus cell culture.

Kramer SM, Gibson UE, Fendly BM, Mohler MA, Drolet DW, Johnston PD.

In Vitro Cell Dev Biol. 1990 Jun;26(6):647-56.

PMID:
2162818
27.

An enzyme-linked immunosorbent assay to study human relaxin in human pregnancy and in pregnant rhesus monkeys.

Lucas C, Bald LN, Martin MC, Jaffe RB, Drolet DW, Mora-Worms M, Bennett G, Chen AB, Johnston PD.

J Endocrinol. 1989 Mar;120(3):449-57.

PMID:
2926311
28.

The effect of changes in muscle function and bone growth on muscle migration.

Grant PG, Buschang PH, Drolet DW, Pickerell C.

Am J Phys Anthropol. 1981 Apr;54(4):547-53.

PMID:
7234992
29.

Invariance of the relative positions of structures attached to long bones during growth: cross-sectional and longitudinal studies.

Grant PG, Buschang PH, Drolet DW, Pickerell C.

Acta Anat (Basel). 1980;107(1):26-34.

PMID:
7405511
30.

Positional relationships of structures attached to long bones during growth. Cross-sectional studies.

Grant PG, Buschang PH, Drolet DW.

Acta Anat (Basel). 1978;102(4):378-84.

PMID:
696224

Supplemental Content

Loading ...
Support Center